Syndax Announces Proposed Public Offering of Common Stock
Syndax Pharmaceuticals plans to offer and sell shares of its common stock through an underwritten public offering. The offering may include pre-funded warrants and a 30-day option for underwriters to purchase an additional 15% of the shares. Goldman Sachs is the book-running manager for this offering, which is conducted under an effective shelf registration statement with the SEC. The proceeds from the offering will be used to support the development of Syndax's innovative cancer therapies, including SNDX-5613 and axatilimab.
- Syndax's public offering can potentially raise necessary capital for the development of its cancer therapies.
- The inclusion of pre-funded warrants may attract a broader range of investors.
- The public offering may lead to dilution of existing shareholders' equity.
- Completion of the offering is contingent on market conditions and other customary closing conditions.
WALTHAM, Mass., Dec. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it plans to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Syndax may, in lieu of common stock, offer and sell to certain investors pre-funded warrants to purchase shares of its common stock in the underwritten public offering. Syndax also expects to grant the underwriters a 30-day option to purchase up to an additional
Goldman Sachs & Co. LLC is acting as book-running manager for the offering.
The shares are being offered pursuant to a "shelf" registration statement previously filed and declared effective by the Securities and Exchange Commission (SEC). A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the website of the SEC at www.sec.gov. When available, copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may be obtained from: Goldman Sachs and Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 866-471-2526, facsimile: 212-902-9316 or by emailing Prospectus-ny@ny.email.gs.com.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, if at all, will be made only by means of a prospectus supplement and accompanying prospectus, which are a part of the effective registration statement.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend," "believe" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. There can be no assurance that Syndax will be able to complete the proposed public offering on the anticipated terms, or at all. Other factors that may cause Syndax's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein, as well as the risks identified in the registration statement and the preliminary prospectus supplement relating to the offering. These forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press release. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Syndax Contacts
Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902
Media Contact
Benjamin Kolinski
benjamin.kolinski@gcihealth.com
Tel 862.368.4464
SNDX-G
View original content:https://www.prnewswire.com/news-releases/syndax-announces-proposed-public-offering-of-common-stock-301445881.html
SOURCE Syndax Pharmaceuticals, Inc.
FAQ
What is Syndax Pharmaceuticals planning regarding its common stock offering?
How much additional stock may be purchased by underwriters in Syndax's offering?
Who is managing Syndax's public offering?
What are the potential uses for the funds raised from Syndax's stock offering?
What risks are associated with Syndax's public stock offering?
